MAP Pharmaceuticals Inc. (MAPP) Gets Inhaled by Allergan Inc. (AGN)
From Insider Monkey - Free Hedge Fund and Insider Trading Data
January 23, 2013 - 2:58pm
Allergan Inc. (NYSE:AGN) announced Tuesday the acquisition of MAP Pharmaceuticals Inc. (NASDAQ:MAPP) for about $958 million in cash. The companies previously agreed to co-promote MAP’s inhalable migraine treatment Levadex if it passed the Food and Drug Administration — and that approval decision should arrive before mid-April. Levadex received a complete response letter last spring based [...]
Continue reading this article »Share This Article: